2,679 Shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC) Acquired by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC acquired a new position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 2,679 shares of the company’s stock, valued at approximately $209,000.

Several other large investors have also recently modified their holdings of the company. D1 Capital Partners L.P. purchased a new stake in GE HealthCare Technologies during the 3rd quarter worth approximately $268,159,000. Van ECK Associates Corp grew its position in GE HealthCare Technologies by 107.3% during the 4th quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after purchasing an additional 2,506,417 shares during the last quarter. State Street Corp grew its position in GE HealthCare Technologies by 7.8% during the 3rd quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after purchasing an additional 1,347,114 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in GE HealthCare Technologies during the 3rd quarter worth approximately $93,713,000. Finally, Jennison Associates LLC grew its position in GE HealthCare Technologies by 124.5% during the 4th quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock worth $133,659,000 after purchasing an additional 948,017 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on GEHC shares. Citigroup boosted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company upped their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Stock Performance

Shares of NASDAQ GEHC opened at $84.76 on Thursday. The company’s fifty day moving average price is $86.52 and its 200 day moving average price is $86.13. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The company has a market capitalization of $38.76 billion, a PE ratio of 19.58, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. On average, research analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.